Nona Biosciences, a global biotech innovator, has announced a major expansion of its integrated discovery and development framework to support early clinical development and Investigator-Initiated Trials (IITs).  

The move extends Nona’s capabilities beyond discovery and IND-enabling activities, bolstering CMC development, toxicology, and GMP manufacturing. 

Through a combination of strategic partnerships, platform acquisitions, and internal technology innovation, Nona aims to help global biopharmaceutical companies fast-track clinical trial initiation without compromising scientific rigor or quality standards. 

The expanded framework leverages Nona’s proprietary platforms—including Harbour Mice, HBICE, Hu-mAtrIx, NonaCarFx, and Modalities-on-Demand—while strengthening preclinical and early clinical capabilities. By tapping into partnerships in China and advancing IITs, Nona offers global partners access to robust infrastructure and operational efficiency, enabling quicker clinical trials with full regulatory compliance. 

“Expanding Nona's technology platforms and capabilities from antibody discovery to early clinic development represents a natural progression of our strategic vision,” said Dr Di Hong, CEO of Nona Biosciences.  

“By combining our proprietary platforms with strategic external collaborations and internal development efforts, we are strengthening our ability to enable efficient clinical translation while remaining focused on building differentiated, scalable technologies.”